Advertisement

Current Treatment Options in Rheumatology

, Volume 4, Issue 4, pp 344–354 | Cite as

Disease Modification in Axial Spondyloarthritis

  • Ejaz Pathan
  • Padmanabha Shenoy
  • Xenofon Baraliakos
Seronegative Arthritis (N Haroon, Section Editor)
  • 26 Downloads
Part of the following topical collections:
  1. Topical Collection on Seronegative Arthritis

Abstract

Purpose of review

The development of advanced treatment options such as biologic agents for axial Spondyloarthritis (axSpA) has led to increased expectations for modification of clinical outcomes in the long-term course of the disease. In this review, we discuss the objective assessments of disease activity as well as progression and the possible role of the currently available treatment options for modification of the disease course.

Recent findings

The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) continues to be a reliable measure of disease progression. The role of continuous use of NSAIDs remains contentious. Reports have shown the disease-modifying nature of currently available therapies including the anti-TNF agents when used early in the disease course. The benefit has been shown to be evident after at least 4 years of treatment. The anti-IL 17 agents also hold promise for preventing radiographic progression. Newer therapies such as the oral JAK inhibitors need further evaluation.

Summary

Disease modification in axial spondyloarthritis which has remained elusive despite clinical improvement with treatment now seems achievable as we start to understand the pathophysiology of this condition better.

Keywords

Axial spondyloarthritis Syndesmophytes mSASSS Disease modification NSAIDs Biologics 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Pathan reports grants from Merck and personal fees from Celgene outside the submitted work. Padmanabha Shenoy and Xenofon Baraliakos declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance •• Of major importance

  1. 1.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol [Internet]. 1994;21(12):2286–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7699630.
  2. 2.
    Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis [Internet]. 2009;68(1):18–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18625618.
  3. 3.
    Brandt J, Listing J, Sieper J, Rudwaleit M, Van Der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha Treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438–44.CrossRefGoogle Scholar
  4. 4.
    Machado P, Landewé RBM, Braun J, Baraliakos X, Hermann K-GA, Hsu B, Baker D, van der Heijde D. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis [Internet]. 2012;71(12):2002–5. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-201999.
  5. 5.
    Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, van de Tempel H, et al. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol [Internet]. 2004;31(1):125–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14705231.
  6. 6.
    Baraliakos X, Listing J, Von Der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis—evidence for major individual variations in a large proportion of patients. J Rheumatol. 2009;36(5):997–1002.CrossRefGoogle Scholar
  7. 7.
    Creemers MCW, Franssen MJAM, Van’t Hof MA, Gribnau FWJ, Van De Putte LBA, Van Riel PLCM. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127–9.CrossRefGoogle Scholar
  8. 8.
    Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Care Res. 2009;61(6):764–71.CrossRefGoogle Scholar
  9. 9.
    Maas F, Arends S, Brouwer E, Bootsma H, Bos R, Wink FR, et al. Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Arthritis Res Ther. 2017;19(1):1–9.CrossRefGoogle Scholar
  10. 10.
    Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910–5.CrossRefGoogle Scholar
  11. 11.
    • Ramiro S, Van Der Heijde D, Van Tubergen A, Stolwijk C, Dougados M, Van Den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455–61. This study showed for the first time the correlation between disease activity and structural damage over time.CrossRefGoogle Scholar
  12. 12.
    Van Tubergen A, Ramiro S, Van Der Heijde D, Dougados M, Mielants H, Landewé R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 2012;71(4):518–23.CrossRefGoogle Scholar
  13. 13.
    Van Der Heijde D, Landewé R, Hermann K, Rudwaleit M, Oostveen A, Connor PO, et al. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol. 2007;34(4):862–70.PubMedGoogle Scholar
  14. 14.
    Maksymowych WP, Wichuk S, Chiowchanwisawakit P, Lambert RG, Pedersen SJ. Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score. J Rheumatol. 2015;42(1):79–86.CrossRefGoogle Scholar
  15. 15.
    Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RGW. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009;60(1):93–102.CrossRefGoogle Scholar
  16. 16.
    Van Der Heijde D, Machado P, Braun J, Hermann KGA, Baraliakos X, Hsu B, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(3):369–73.CrossRefGoogle Scholar
  17. 17.
    Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72(1):23–8.CrossRefGoogle Scholar
  18. 18.
    Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54(9):2845–51.CrossRefGoogle Scholar
  19. 19.
    Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73(12):2137–43.CrossRefGoogle Scholar
  20. 20.
    Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008;10(5):1–8.CrossRefGoogle Scholar
  21. 21.
    Pedersen SJ, Sørensen IJ, Lambert RG, Hermann KG, Garnero P, Johansen JS, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. 2011;63(12):3789–800.CrossRefGoogle Scholar
  22. 22.
    Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis [Internet]. 1993;52(5):343–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1005047&tool=pmcentrez&rendertype=abstract.
  23. 23.
    Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572–4.CrossRefGoogle Scholar
  24. 24.
    Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60(11):3257–62.CrossRefGoogle Scholar
  25. 25.
    Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, Van Der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56(6):1846–53.CrossRefGoogle Scholar
  26. 26.
    Daoussis D, Liossis SNC, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62(1):150–8.CrossRefGoogle Scholar
  27. 27.
    Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592–7.CrossRefGoogle Scholar
  28. 28.
    Wehmeyer C, Frank S, Beckmann D, Böttcher M, Cromme C, König U, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330):1–12.CrossRefGoogle Scholar
  29. 29.
    • Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, et al. Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheumatol. 2017;69(9):1796–806. This study shows Macrophage migration inhibitory factor as a possible biomarker of disease progression in AS.CrossRefGoogle Scholar
  30. 30.
    Park J-H, Lee S-G, Jeon Y-K, Park E-K, Suh Y-S, Kim H-O. Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis A preliminary 2-year longitudinal study. Medicine (Baltimore) [Internet]. 2017;96:33–7854. Available from:  https://doi.org/10.1097/MD.0000000000007854.
  31. 31.
    Hartl A, Sieper J, Syrbe U, Listing J, Hermann KG, Rudwaleit M, et al. Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Res Ther. 2017;19(1):1–11.CrossRefGoogle Scholar
  32. 32.
    Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol [Internet]. 1976;5(1):60–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/816001.
  33. 33.
    Wanders A, Heijde D van der, Landewé R, Béhier J-M, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum [Internet]. 2005;52(6):1756–65. Available from: http://doi.wiley.com/10.1002/art.21054.
  34. 34.
    • Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438–43. This study showed that continous vs intermittent intake of Diclofenac did not lead to any difference in terms of radiographic progression.CrossRefGoogle Scholar
  35. 35.
    Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol [Internet]. Nature Publishing Group; 2010;6(2):75–81. Available from:  https://doi.org/10.1038/nrrheum.2009.258.
  36. 36.
    Ward MM. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis Rheum. 2005;52(6):1634–6.CrossRefGoogle Scholar
  37. 37.
    Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017;56(1):95–102.CrossRefGoogle Scholar
  38. 38.
    Van Der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.CrossRefGoogle Scholar
  39. 39.
    Van Der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.CrossRefGoogle Scholar
  40. 40.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667–75.CrossRefGoogle Scholar
  41. 41.
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha Antibody infliximab. Ann Rheum Dis. 2005;64(10):1462–6.CrossRefGoogle Scholar
  42. 42.
    Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology. 2007;46(9):1450–3.CrossRefGoogle Scholar
  43. 43.
    •• Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54. This study showed that anti-TNF therapy did indeed retard radiographic progression.PubMedPubMedCentralGoogle Scholar
  44. 44.
    •• Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710–5.  https://doi.org/10.1136/annrheumdis-2012-202698. Another study that showed that anti-TNF therapy did retard radiographic progression after 8 year follow up.CrossRefPubMedGoogle Scholar
  45. 45.
    • Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070–7. This study showed that IL-17 inhibitors also retard radiographic progression.CrossRefGoogle Scholar
  46. 46.
    Van Der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–7.CrossRefGoogle Scholar
  47. 47.
    Kavanaugh A, Mease PJ, Gomez-reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised , placebo-controlled trial with apremilast , an oral phosphodiesterase 4 inhibitor. 2014;1020–6.Google Scholar
  48. 48.
    Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast , an oral phosphodiesterase 4 inhibitor , in the treatment of moderate to severe psoriasis : results from a phase IIb randomized , controlled study. 2013;1–9.Google Scholar
  49. 49.
    Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475–80.CrossRefGoogle Scholar
  50. 50.
    Worth C, Bowness P, Hussein Al-Mossawi M. Novel therapeutic targets in axial spondyloarthritis. Curr Treatm Opt Rheumatol [Internet]. 2018;4(2):174–82. Available from: http://link.springer.com/10.1007/s40674-018-0095-1.
  51. 51.
    Schaible H-G, Ebersberger A, Von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci [internet]. 2002;966:343–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12114291.
  52. 52.
    Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445–52.CrossRefGoogle Scholar
  53. 53.
    Al-Mossawi MH, Chen L, Fang H, Ridley A, De Wit J, Yager N, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun [Internet]. Springer US; 2017;8(1):1–11. Available from:  https://doi.org/10.1038/s41467-017-01771-2

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Ejaz Pathan
    • 1
  • Padmanabha Shenoy
    • 2
  • Xenofon Baraliakos
    • 3
  1. 1.Spondylitis ProgramToronto Western Hospital, UHNTorontoCanada
  2. 2.Centre for Arthritis and Rheumatism Excellence (CARE)CochinIndia
  3. 3.Department of Rheumatology, Rheumazentrum Ruhrgebiet HerneRuhr-University BochumBochumGermany

Personalised recommendations